Incisive Genetics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$9.4M
- Investors
-
10
Incisive Genetics General Information
Description
Developer of a lipid nanoparticle delivery platform designed to effectively and safely deliver gene-editing machinery to the site of application. The company develops transformational lipid nanoparticle-based gene-editing platforms for genetic therapies and provides an effective CRISPR-based gene therapy, enabling pharmaceutical businesses to conveniently deliver drugs to patients without causing any harm.
Contact Information
Website
www.incisivegenetics.comCorporate Office
- 200 - 980 George Street
- Vancouver, British Columbia V6A 0H9
- Canada
Corporate Office
- 200 - 980 George Street
- Vancouver, British Columbia V6A 0H9
- Canada
Incisive Genetics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Seed Round | 27-Jun-2022 | $9.4M | Completed | Generating Revenue | ||
| 4. Angel (individual) | 12-Jul-2021 | Completed | Generating Revenue | |||
| 3. Angel (individual) | 22-Sep-2020 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2018 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Incisive Genetics Patents
Incisive Genetics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026028149-A1 | Guide rnas for editing serpina1, and compositions and methods relating thereto | Pending | 01-Aug-2024 | ||
| AU-2025376352-A1 | Dual guide rnas for allele-selective or specific gene editing, and compositions and methods relating thereto | Pending | 14-May-2024 | ||
| WO-2025238579-A1 | Dual guide rnas for allele-selective or specific gene editing, and compositions and methods relating thereto | Pending | 14-May-2024 | ||
| AU-2025378053-A1 | Guide rnas for allele-selective gene editing, and compositions and methods relating thereto | Pending | 14-May-2024 | ||
| WO-2025238578-A1 | Guide rnas for allele-selective gene editing, and compositions and methods relating thereto | Pending | 14-May-2024 | C12N15/907 |
Incisive Genetics Signals
Incisive Genetics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Conconi Growth Partners | Family Office | Minority | ||
| MacHall Group | Other | Minority | ||
| Robinson Sauder Family Office | Family Office | Minority | ||
| Saltagen Ventures | Venture Capital | Minority | ||
| Velocity Capital Management | PE/Buyout | Minority |
Incisive Genetics FAQs
-
When was Incisive Genetics founded?
Incisive Genetics was founded in 2018.
-
Where is Incisive Genetics headquartered?
Incisive Genetics is headquartered in Vancouver, Canada.
-
What is the size of Incisive Genetics?
Incisive Genetics has 13 total employees.
-
What industry is Incisive Genetics in?
Incisive Genetics’s primary industry is Drug Delivery.
-
Is Incisive Genetics a private or public company?
Incisive Genetics is a Private company.
-
What is Incisive Genetics’s current revenue?
The current revenue for Incisive Genetics is .
-
How much funding has Incisive Genetics raised over time?
Incisive Genetics has raised $12.2M.
-
Who are Incisive Genetics’s investors?
Conconi Growth Partners, MacHall Group, Robinson Sauder Family Office, Saltagen Ventures, and Velocity Capital Management are 5 of 10 investors who have invested in Incisive Genetics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process